PSB 069 (CAS 78510-31-3)
See product citations (1)
Available in US only.
QUICK LINKS
PSB 069 is a chemical compound utilized as a research tool in the study of purinergic receptors, specifically the P2Y12 subtype. This compound is classified as a selective antagonist, which allows researchers to investigate the physiological role of P2Y12 receptors in platelet aggregation and thrombus formation. In experimental models, PSB 069 is employed to block the action of endogenous agonists at P2Y12 receptors, thereby helping to dissect the signaling pathways involved in platelet activation. Additionally, it is used in the exploration of P2Y12 receptor function in the central nervous system, where these receptors are implicated in processes such as neurodegeneration and inflammation. Its application extends to the examination of P2Y12 receptors in the development of novel antiplatelet agents for research purposes.
PSB 069 (CAS 78510-31-3) References
- Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). | Baqi, Y., et al. 2009. Purinergic Signal. 5: 91-106. PMID: 18528783
- Ecto-nucleotidase inhibitors: recent developments in drug discovery. | Baqi, Y. 2015. Mini Rev Med Chem. 15: 21-33. PMID: 25694081
- Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. | Draganov, D., et al. 2015. Sci Rep. 5: 16222. PMID: 26552848
- Distinct purinergic signaling pathways in prepubescent mouse spermatogonia. | Fleck, D., et al. 2016. J Gen Physiol. 148: 253-71. PMID: 27574293
- Generation and characterization of polyclonal and monoclonal antibodies to human NTPDase2 including a blocking antibody. | Pelletier, J., et al. 2017. Purinergic Signal. 13: 293-304. PMID: 28409324
- Investigation of new quinoline derivatives as promising inhibitors of NTPDases: Synthesis, SAR analysis and molecular docking studies. | Hayat, K., et al. 2019. Bioorg Chem. 87: 218-226. PMID: 30903944
- Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epithelia. | van Heusden, C., et al. 2020. Am J Physiol Lung Cell Mol Physiol. 318: L356-L365. PMID: 31800264
- Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin. | Liu, J., et al. 2020. Drug Des Devel Ther. 14: 285-296. PMID: 32021111
- Repurposing bioactive compounds for treating multidrug-resistant pathogens. | Hummell, NA. and Kirienko, NV. 2020. J Med Microbiol. 69: 881-894. PMID: 32163353
- Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39. | Jeffrey, JL., et al. 2020. J Med Chem. 63: 13444-13465. PMID: 32786396
- Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. | Kumar, M. and Lowery, RG. 2021. SLAS Discov. 26: 740-746. PMID: 33402044
- Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer. | Manouchehri, JM., et al. 2022. Front Oncol. 12: 855032. PMID: 35515134
- Forging Ahead the Repositioning of Multitargeted Drug Ivermectin. | Atmakuri, S., et al. 2023. Curr Drug Deliv. 20: 1049-1066. PMID: 35578879
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSB 069, 5 mg | sc-204216 | 5 mg | $176.00 | |||
| US: Only available in the US | ||||||
PSB 069, 10 mg | sc-204216A | 10 mg | $728.00 | |||
| US: Only available in the US | ||||||